At Market Issuance Sales AgreementPluristem Therapeutics Inc • July 7th, 2017 • Biological products, (no disgnostic substances) • New York
Pluristem Therapeutics Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”), with FBR Capital Markets & Co. (“FBR”), MLV & Co. LLC (“MLV”) and Oppenheimer & Co. Inc. (“Oppenheimer”; each of FBR, MLV and Oppenheimer individually an “Agent” and collectively, the “Agents”), as follows:
